Should you buy Tilray stock now?
No, the technical signal for Tilray is currently SELL. Tilray trades at $4.46 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.058 with rising momentum (signal: -0.141); RSI is at 50.4 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $7.84 points to 76.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Tilray stock?
The average analyst price target for Tilray is $7.84. The current price is $4.46, which gives an upside of 76.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $7.06 and $8.62.
Is Tilray a dividend stock?
No, Tilray does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Tilray stock?
Tilray is rated as a stock with extreme risk. the annual standard deviation is 123.3%, which classifies the stock as extreme risk.
Is Tilray overvalued?
No, Tilray is considered undervalued based on the analyst price target (76.0% upside). Tilray has the following valuation ratios: a P/S ratio of 0.6, a P/B ratio of 0.4. The analyst price target suggests that the stock is undervalued by 76.0%.
Is Tilray overbought?
No, Tilray is not overbought. RSI is at 50.4 (neutral zone). The technical indicators show: RSI is at 50.4 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.0% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Tilray earnings report?
The date of the next earnings report for Tilray has not been published yet. Check the company's investor calendar for updates.
Is Tilray shorted?
Yes, Tilray is shorted with 13.2% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Tilray stock?
No, insiders are not buying Tilray shares – they are net sellers. Over the last 3 months, insiders have made 2 purchases and 11 sales. On a net basis, 3,907,233 $ worth of shares were sold. Across the last 20 reported transactions, the split is 4 purchases and 16 sales, with a net 4,725,257 $ sold. Active sellers include SIMON IRWIN D, Merton Carl A, Gendel Mitchell and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Tilray a good stock?
Based on our total score, Tilray is rated as a poor stock with a total score of 26 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 57/100, Quality: 18/100, Momentum: 3/100. In addition: analysts see 76.0% upside to the price target; technical signal: Strong Sell. Whether Tilray is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Tilray stock?
The outlook for Tilray based on current data: the average analyst price target is $7.84 (+76.0%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Tilray stock rising?
Tilray is rising right now. The technical indicators show: the price is 4.0% above the 20-day average; short interest is 13.2% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Tilray go?
The average analyst price target for Tilray is $7.84, which corresponds to a potential gain of 76.0% from the current price of $4.46. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Tilray fall?
We lack enough history to give a specific floor for Tilray. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Tilray do?
Tilray Brands Inc. driver en bred forretning, der handler om cannabis, men de laver også meget andet. De tjener primært penge på at dyrke, forske i og distribuere medicinske cannabisprodukter. Tilray sælger både til medicinsk brug og til rekreativt brug, hvor det er lovligt.
... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Tilray as an investment.
Did Tilray raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Tilray. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Tilray making money or losing money?
No, Tilray is currently not making money — the company is losing money with a negative profit margin of -13.3%, a noticeable loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Tilray go bankrupt?
The bankruptcy risk of Tilray is rated as elevated. Altman Z2 (a model for assessing financial distress) is -3.62 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 41% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Tilray have a lot of debt?
No, Tilray has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 41%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Tilray service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -0.7x, and net debt equals 11.5 years of earnings (EBITDA).
